A three-part study to investigate the incidence and potential etiologies of tadalafil-associated back pain or myalgia

A. D. Seftel, J. Farber, J. Fletcher, M. C. Deeley, A. Elion-Mboussa, A. Hoover, A. Yu, P. Fredlund

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

The potential mechanisms underlying back pain and/or myalgia experienced by men taking tadalafil were investigated. An integrated analysis of 10 placebo-controlled tadalafil clinical trials (N = 1846) showed that the incidence of back pain and/or myalgia was 9.4% in patients receiving tadalafil 10 mg (N = 394), 8.3% in patients receiving tadalafil 20 mg (N = 883) and 3.7% in placebo-treated patients (N = 569). One (0.3%) patient receiving tadalafil 10 mg, six (0.7%) patients receiving tadalafil 20 mg, and no patients receiving placebo discontinued treatment due to back pain and/or myalgia. In a prospective study in healthy volunteers, no substantial changes were observed in laboratory markers indicative of inflammation or muscle damage, and tadalafil did not affect renal plasma flow nor produce lumbar or gluteal myositis by positron emission tomography scan or magnetic resonance imaging. Although the mechanism of back pain and/or myalgia remains unknown, these events appear to be self-limiting and a general effect of phosphodiesterase 5 inhibition.

Original languageEnglish (US)
Pages (from-to)455-461
Number of pages7
JournalInternational Journal of Impotence Research
Volume17
Issue number5
DOIs
StatePublished - Sep 1 2005

Keywords

  • Back pain
  • Impotence
  • Myositis
  • Phosphodiesterase inhibitors

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'A three-part study to investigate the incidence and potential etiologies of tadalafil-associated back pain or myalgia'. Together they form a unique fingerprint.

  • Cite this